Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Trial of Ad26.RSV.preF-based Vaccine in Adults 18–59 Years
2021-001909-77Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2021
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in respiratory syncytial virus disease (RSV) and pulmonary infection comparing Ad26.RSV.preF-based Vaccine with Placebo (2 arms). Primary endpoint: Solicited local and systemic adverse events. Started Jun 2021; status: completed.
02
Drugs
Ad26.RSV.preF
03
Conditions
respiratory syncytial virus disease (RSV)pulmonary infection
Beyond the preview
Go deeper on 2021-001909-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001909-77.